EUCTR2013-001231-51-ROActive, not recruitingPhase 1
Efficacy and Immunogenicity Study of Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Healthy Children Aged 6 to 35 Months
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Sanofi Pasteur
- Enrollment
- 5,805
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Healthy children aged 6 to less than 36 months not previously vaccinated against influenza.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 9000
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •At risk” children according to the definition from the Advisory Committee on Immunization Practices (ACIP).
Investigators
Similar Trials
Active, not recruiting
Phase 1
Efficacy and Immunogenicity Study of Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Healthy Children Aged 6 to 35 MonthsPrevention of influenza infection in children aged 6 to 35 monthsMedDRA version: 17.0Level: LLTClassification code 10022001Term: Influenza (epidemic)System Organ Class: 100000004862EUCTR2013-001231-51-GRSanofi Pasteur9,000
Active, not recruiting
Phase 1
Efficacy and Immunogenicity Study of Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Healthy Children Aged 6 to 35 MonthsPrevention of influenza infection in children aged 6 to 35 monthsMedDRA version: 16.1Level: LLTClassification code 10022001Term: Influenza (epidemic)System Organ Class: 100000004862EUCTR2013-001231-51-ITSanofi Pasteur9,000
Active, not recruiting
Phase 1
Efficacy and Immunogenicity Study of Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Healthy Children Aged 6 to 35 MonthsPrevention of influenza infection in children aged 6 to 35 monthsMedDRA version: 16.1Level: LLTClassification code 10022001Term: Influenza (epidemic)System Organ Class: 100000004862EUCTR2013-001231-51-ESSanofi Pasteur9,000
Active, not recruiting
Phase 1
Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or Concomitantly with Two Other Vaccines in Healthy AdolescentsMeningococcal infectionMedDRA version: 20.0Level: PTClassification code 10027274Term: Meningococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-001665-37-ITSANOFI PASTEUR464
Active, not recruiting
Phase 1
Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or Concomitantly with Two Other Vaccines in Healthy AdolescentsMeningococcal infectionMedDRA version: 20.0Level: PTClassification code 10027274Term: Meningococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-001665-37-HUSanofi Pasteur464